Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2011-05-03
2011-05-03
Yu, Misook (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
C530S350000, C530S391700
Reexamination Certificate
active
07935785
ABSTRACT:
The invention provides isolated MMP-2, MMP-9 and MT1-MMP selective substrate polypeptides or functional peptidomimetics. The selective substrate polypeptides contain the following sequences: MMP-2 selective substrate polypeptides contain SEQ ID NOS:1-27, MMP-9 selective substrate polypeptides contain SEQ ID NOS:28-35, and MT1-MMP selective substrate polypeptide contain SEQ ID NOS:36-40. In addition, the invention provides a method of preferentially directing a moiety to a site of MMP-2 activity by administering to a subject an effective amount of an isolated MMP-2 selective substrate polypeptide containing SEQ ID NOS:45-47 linked to a moiety. Also provided is a method of preferentially directing a moiety to a site of MMP-9 activity by administering to a subject an effective amount of an isolated MMP-9 selective substrate polypeptide containing SEQ ID NO:44 linked to a moiety, and preferentially directing a moiety to a site of MT1-MMP activity by administering to a subject an effective amount of an isolated MT1-MMP selective substrate polypeptide containing SEQ ID NOS:36-40 linked to a moiety.
REFERENCES:
patent: 5316906 (1994-05-01), Haugland et al.
patent: 5518912 (1996-05-01), Zasloff et al.
patent: 6399075 (2002-06-01), Howley et al.
patent: 2004/0031072 (2004-02-01), La Rosa et al.
patent: WO0109165 (2002-02-01), None
Gianluigi et al, Science, 277:225-227, 1997.
Chen et al, J Biol Chem, 277: 4485-4491, 2002, IDS, p. 1, last line.
Turk et al, Nature Bio. 19:661-667, 2001.
Sequence search result (La Rosa), 2010.
Bergers et al., “Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis,”Nature Cell Biol.2:737-744 (2000).
Birkendal-Hansen, “Proteolytic remodeling of extracellular matrix,”Curr. Opin. Cell Biol.7:728-735 (1995).
Bowie et al., “Deciphering the message in protein sequences: tolerance to amino acid substitutions,”Science247:1306-1310 (1990).
Burger's Medicinal Chemistry and Drug DiscoveryEditor Manfred E. Wolff, Ch. 15, pp. 619-620, John Wiley & Sons Inc., New York, New York (1995).
Burgess et al., “Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue,”J. Cell. Biol.111:2129-2138 (1990).
Chen et al., “A Unique Substrate Recognition Profile for Matrix Metalloproteinase-2,”J. Biol. Chem.277:4485-4491 (2002).
Coussens et al., “MMP-9 Supplied by Bone Marrow-Derived Cells Contributes to Skin Carcinogenesis,”Cell103:481-490 (2000).
DeFeo-Jones et al., “A peptide-doxorubicin ‘prodrug’ activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo,”Nature Med.6:1248-1252 (2000).
Deng et al., “Substrate Specificity of Human Collagenase 3 Assessed Using a Phage-displayed Peptide Library,”J. Biol. Chem.275:31422-31427 (2000).
Denmeade et al., “Enzymatic Activation of Doxorubicin-Peptide Prodrug by Prostate-Specific Antigen,”Cancer Res.58:2537-2540 (1998).
Fersht,Enzyme Structure and Mechanism,W.H. Freeman and Co. (1977).
Folkman, “Angiogenesis in cancer, vascular, rheumatoid and other disease,”Nature Med.1:27-31 (1995).
Goldman et al., “Targeted Gene Delivery to Kaposi's Sarcoma Cells via the Fibroblast Growth Factor Receptor,”Cancer Res.57:1447-1451 (1997).
Gura “Systems for identifying new drugs are often faulty,”Science278:1041-1042 (1997).
Jain et al., “Barriers to drug delivery in solid tumors,”Scientific AmericanJul. 1994.
Koivunen et al., “Tumor targeting with a selective gelatinase inhibitor,”Nature Biotech.17:768-774 (1999).
Kridel et al., “Substrate Hydrolosis by Matrix Metalloproteinase-9,”J. Biol. Chem.276:20572-20578 (2001).
Kridel et al., “A Substrate Phage Enzyme-Linked Immunosorbent Assay to Profile Panels of Proteases,”Anal. Biochem.294:176-184 (2001).
Lazar et al., “Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities,”Mol. Cell. Biol.8:1247-1252 (1988).
Murphy and Crabbe, “Gelatinases A and B,”Methods Enzymol.248:470-484 (1995).
Netzel-Arnett et al., “Comparative Sequence Specificities of Human 72-and 92-kDa Gelatinases (Type IV Collagenases) and Pump (Matrilysin),”Biochemistry32:6427-6432 (1993).
Netzel-Arnett et al., “Sequence Specificities of Human Fibroblast and Neutrophil Collagenases,”J. Biol. Chem.266:6747-6755 (1991).
Ohkubo et al., “Identification of Substrate Sequences for Membrane Type-1 Matrix Metalloproteinase Using Bacteriophage Peptide Display Library,”Biochem. Biophys. Res. Comm.266:308-313 (1999).
Ohuchi et al., “Membrane Type 1 Matrix Metalloproteinase Digests Interstitial Collagens and Other Extracellular Matrix Macromolecules,”J. Biol. Chem.272:2446-2451 (1997).
Rak et al., “Consequences of angiogenesis for tumor progression, metastasis and cancer therapy,”Anti-Cancer Drugs6:3-18 (1995).
Schechter and Berger, “On the Size of the Active Site in Proteases. I. Papain,”Biochem. and Biophys. Res. Comm.27:157-162 (1967).
Smith and Petrenko “Phage Display”Chem. Rev.97:391-410 (1997).
Smith et al., “Rapid Identification of Highly Active and Selective Substrates for Stromelysin and Matrilysin Using Bacteriophage Peptide Display Libraries,”J. Biol. Chem.270:6440-6449 (1995).
Smith et al., “Building Synthetic Antibodies as Adhesive Ligands for Intergrins,”J. Biol. Chem.269:32788-32795 (1994).
Weissleder et al., “In vivo imaging of tumors with protease-activated near-infrared fluorescent probes,”Nature Biotech.17:375-378 (1999).
NCBI Accession No. P28618 (Dec. 1992).
PIR Database, Accession No. S54424, Apr. 1997.
PIR Database, Accession No. A45185, Sep. 1993.
PIR Database, Accession No. D71810, Feb. 12, 1999.
Chen Emily I.
Kridel Steven J.
Smith Jeffrey W.
Jones Day
Sanford-Burnham Medical Research Institute
Yao Lei
Yu Misook
LandOfFree
Selective substrates for matrix metalloproteinases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selective substrates for matrix metalloproteinases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective substrates for matrix metalloproteinases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2658104